Castration Resistant Prostatic Neoplasms Completed Phase 1 Trials for Cetrelimab (DB15421)
Also known as: Prostate Neoplasms, Castration-resistant / Castration-Resistant Prostatic Neoplasms / Prostatic Neoplasms, Castration-Resistant
| Indication | Status | Phase |
|---|---|---|
| DBCOND0129140 (Castration Resistant Prostatic Neoplasms) | Completed | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03551782 | A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer | Treatment |